Pipeline
TechnoPhage currently holds a well-balanced and diversified product portfolio addressing key therapeutic and non-therapeutic areas while simultaneously being agile in meeting the challenges of the rapidly evolving pharmaceutical industry.
Therapeutic products
Infection
DiscoveryPreclinicalIND/CTAPhase IPhase IIPhase III
- Chronic ulcers (TP-102) 84%
- Respiratory infection (TP-122) 49.8%
- Urinary tract infection (TP-164) 29%
Neuroscience
DiscoveryPreclinicalIND/CTAPhase IPhase IIPhase III
- Parkinson’s disease (TZ-113) 41.5%
- Spinal cord injury (TZ-161) 52.5%
- Undisclosed indication (TA-191) 16%
Ophthalmology
DiscoveryPreclinicalIND/CTAPhase IPhase IIPhase III
- Undisclosed indication (TA-182) 16%
Non-therapeutic products
Biomarkers
DiscoveryPreclinicalClinical
- Biomarker (TA-111C) 65%
- Biomarker (TA-211) 32%
Others
DiscoveryPreclinical
- Dietary Supplement (C1/PD-00105) 100%
Therapeutic products
![infection-mob2022](http://technophage.pt/wp-content/uploads/2023/03/infection-2023.jpg)
![neuro-science-mobile_0624](http://technophage.pt/wp-content/uploads/2024/06/neuro-science-mobile_0624.jpg)
![ophthalmology-mob2022](http://technophage.pt/wp-content/uploads/2023/03/ophthalmology-2023.jpg)
Non-therapeutic products
![biomarkers-mob2022](http://technophage.pt/wp-content/uploads/2023/03/biomarkers-2023.jpg)
![others-mobile_0624](http://technophage.pt/wp-content/uploads/2024/06/others-mobile_0624.jpg)